Concurrent Session 7: Clinical Aspects and Outcomes in OA

Moderators: Armaghan Mahmoudian & Grace Lo 

Sarcopenic Obesity: Why Is It Important in OA?
Kristine Godziuk

• Sarcopenic obesity development, health impacts, and diagnostic approaches.
• Evidence on the relevance of sarcopenic obesity for OA incidence, progression, and management.
• Implications of weight loss, and sarcopenic obesity prevention and treatment strategies. 

Abstract Presentations:

48 WORK-RESTRICTING MUSCULOSKELETAL PAIN IN PATIENTS TREATED WITH BARIATRIC SURGERY OR USUAL OBESITY CARE — RESULTS FROM SWEDISH OBESE SUBJECTS, A CONTROLLED INTERVENTION STUDY WITH 20 YEARS FOLLOW-UP               
Stefan Lohmander

49 A COMPARISON OF SURGICAL OUTCOME AND EQUITABLE ACCESS FOR HIP, KNEE AND LUMBAR SPINE SURGERY FOR ENDSTAGE OSTEOARTHRITIS.         
Y. Raja Rampersaud 

50 EFFICACY OF XT-150, A NOVEL NON-VIRAL GENE THERAPY DELIVERING IL-10v, ON MODERATE TO SEVERE PAIN DUE TO KNEE OSTEOARTHRITIS: PATIENT SUBGROUP ANALYSIS                
Howard Rutman

51 SGLT2 INHIBITORS VS. GLP1 AGONISTS AS TREATMENTS FOR OSTEOARTHRITIS              
S. Reza Jafarzadeh

52 THE OARSI JOINT EFFORT INITIATIVE’S PRIORITIES FOR OSTEOARTHRITIS MANAGEMENT PROGRAM IMPLEMENTATION AND RESEARCH 2024-2028 
Jocelyn L. Bowden